Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 35, Issue 1, Pages 11–21
http://dx.doi.org/10.1155/2013/748095
Review Article

Coding and Noncoding Gene Expression Biomarkers in Mood Disorders and Schizophrenia

1Department of Psychiatry and Human Behavior, Functional Genomics Laboratory, University of California, Irvine, CA 92697-4260, USA
2Department of Psychiatry Research, Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, 75-59 263rd Street, Glen Oaks, NY 11004, USA
3The Feinstein Institute for Medical Research, 350 Community Drive, Manhasset, NY 11030, USA
4Department of Psychiatry and Behavioral Science, Albert Einstein College of Medicine of Yeshiva University, 1300 Morris Park Avenue, Belfer Room 403, Bronx, NY 10461, USA

Received 20 December 2012; Accepted 20 February 2013

Academic Editor: Daniel Martins-de-Souza

Copyright © 2013 Firoza Mamdani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. J. L. Murray and A. D. Lopez, The Global Burden of Disease, WHO, Geneva, Switzerland, 1998.
  2. M. Kato and A. Serretti, “Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder,” Molecular Psychiatry, vol. 15, no. 5, pp. 473–500, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. A. K. Malhotra, T. Lencz, C. U. Correll, and J. M. Kane, “Genomics and the future of pharmacotherapy in psychiatry,” International Review of Psychiatry, vol. 19, no. 5, pp. 523–530, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Cruceanu, M. Alda, G. Rouleau, and G. Turecki, “Response to treatment in bipolar disorder,” Current Opinion in Psychiatry, vol. 24, no. 1, pp. 24–28, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Narasimhan and F. W. Lohoff, “Pharmacogenetics of antidepressant drugs: current clinical practice and future directions,” Pharmacogenomics, vol. 13, no. 4, pp. 441–464, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. J.-P. Zhang, T. Lencz, and A. K. Malhotra, “D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis,” American Journal of Psychiatry, vol. 167, no. 7, pp. 763–772, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Bromberg, Y. Bersudsky, J. Levine, and G. Agam, “Global leukocyte DNA methylation is not altered in euthymic bipolar patients,” Journal of Affective Disorders, vol. 118, no. 1–3, pp. 234–239, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Carrard, A. Salzmann, A. Malafosse, and F. Karege, “Increased DNA methylation status of the serotonin receptor 5HTR1A gene promoter in schizophrenia and bipolar disorder,” Journal of Affective Disorders, vol. 132, no. 3, pp. 450–453, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. Z. Kaminsky, M. Tochigi, P. Jia et al., “A multi-tissue analysis identifies HLA complex group 9 gene methylation differences in bipolar disorder,” Molecular Psychiatry, vol. 17, pp. 728–740, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Kinoshita, S. Numata, A. Tajima et al., “DNA methylation signatures of peripheral leukocytes in schizophrenia,” NeuroMolecular Medicine, vol. 15, no. 1, pp. 95–101, 2013. View at Publisher · View at Google Scholar
  11. A. Menke, T. Klengel, and E. B. Binder, “Epigenetics, depression and antidepressant treatment,” Current Pharmaceutical Design, vol. 18, no. 36, pp. 5879–5889, 2012. View at Publisher · View at Google Scholar
  12. M. Schroeder, M. O. Krebs, S. Bleich, and H. Frieling, “Epigenetics and depression: current challenges and new therapeutic options,” Current Opinion in Psychiatry, vol. 23, no. 6, pp. 588–592, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. V. Vialou, J. Feng, A. J. Robison, and E. J. Nestler, “Epigenetic mechanisms of depression and antidepressant action,” Annual Review of Pharmacology and Toxicology, vol. 53, pp. 59–87, 2013. View at Publisher · View at Google Scholar
  14. J. P. Lopez, F. Mamdani, B. Labonte et al., “Epigenetic regulation of BDNF expression according to antidepressant response,” Molecular Psychiatry, vol. 18, pp. 398–399, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Dwivedi, “Brain-derived neurotrophic factor: role in depression and suicide,” Neuropsychiatric Disease and Treatment, vol. 5, no. 1, pp. 433–449, 2009. View at Google Scholar · View at Scopus
  16. M. L. Molendijk, B. A. A. Bus, P. Spinhoven et al., “Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment,” Molecular Psychiatry, vol. 16, no. 11, pp. 1088–1095, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. J. C. Chang, E. C. Wooten, A. Tsimelzon et al., “Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer,” The Lancet, vol. 362, no. 9381, pp. 362–369, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Nagasaki and Y. Miki, “Molecular prediction of the therapeutic response to neoadjuvant chemotherapy in breast cancer,” Breast Cancer, vol. 15, no. 2, pp. 117–120, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Zembutsu, Y. Suzuki, A. Sasaki et al., “Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling,” International Journal of Oncology, vol. 34, no. 2, pp. 361–370, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. A. J. Schetter, S. Y. Leung, J. J. Sohn et al., “MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma,” Journal of the American Medical Association, vol. 299, no. 4, pp. 425–436, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. M. M. Kittleson, K. M. Minhas, R. A. Irizarry et al., “Gene expression in giant cell myocarditis: altered expression of immune response genes,” International Journal of Cardiology, vol. 102, no. 2, pp. 333–340, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Marziliano, M. Grasso, A. Pilotto et al., “Transcriptomic and proteomic analysis in the cardiovascular setting: unravelling the disease?” Journal of Cardiovascular Medicine, vol. 10, no. 5, pp. 433–442, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. S. J. Matkovich, D. J. van Booven, K. A. Youker et al., “Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support,” Circulation, vol. 119, no. 9, pp. 1263–1271, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. R. V. Saveanu and C. B. Nemeroff, “Etiology of depression: genetic and environmental factors,” Psychiatric Clinics of North America, vol. 35, no. 1, pp. 51–71, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. B. Rollins, M. V. Martin, L. Morgan, and M. P. Vawter, “Analysis of whole genome biomarker expression in blood and brain,” American Journal of Medical Genetics B, vol. 153, no. 4, pp. 919–936, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. C.-C. Liew, J. Ma, H.-C. Tang, R. Zheng, and A. A. Dempsey, “The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool,” Journal of Laboratory and Clinical Medicine, vol. 147, no. 3, pp. 126–132, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. P. F. Sullivan, C. Fan, and C. M. Perou, “Evaluating the comparability of gene expression in blood and brain,” American Journal of Medical Genetics B, vol. 141, no. 3, pp. 261–268, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. P. A. Sequeira, M. V. Martin, and M. P. Vawter, “The first decade and beyond of transcriptional profiling in schizophrenia,” Neurobiology of Disease, vol. 45, no. 1, pp. 23–36, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. M. P. Vawter, E. Ferran, B. Galke, K. Cooper, W. E. Bunney, and W. Byerley, “Microarray screening of lymphocyte gene expression differences in a multiplex schizophrenia pedigree,” Schizophrenia Research, vol. 67, no. 1, pp. 41–52, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. M. T. Tsuang, N. Nossova, T. Yager et al., “Assessing the validity of blood-based gene expression profiles for the classification of schizophrenia and bipolar disorder: a preliminary report,” American Journal of Medical Genetics B, vol. 133, no. 1, pp. 1–5, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. S. J. Glatt, I. P. Everall, W. S. Kremen et al., “Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 43, pp. 15533–15538, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. F. A. Middleton, C. N. Pato, K. L. Gentile et al., “Gene expression analysis of peripheral blood leukocytes from discordant sib-pairs with schizophrenia and bipolar disorder reveals points of convergence between genetic and functional genomic approaches,” American Journal of Medical Genetics B, vol. 136, no. 1, pp. 12–25, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. E. McNeill and V. D. van, “MicroRNAs shape the neuronal landscape,” Neuron, vol. 75, pp. 363–379, 2012. View at Publisher · View at Google Scholar
  34. E. Gardiner, N. J. Beveridge, J. Q. Wu et al., “Imprinted DLK1-DIO3 region of 14q32 defines a schizophrenia-associated miRNA signature in peripheral blood mononuclear cells,” Molecular Psychiatry, vol. 17, pp. 827–840, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. C.-Y. Lai, S.-L. Yu, M. H. Hsieh et al., “MicroRNA expression Aberration as potential peripheral blood biomarkers for Schizophrenia,” PLoS One, vol. 6, no. 6, Article ID e21635, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Chen, N. Wang, M. Burmeister, and M. G. McInnis, “MicroRNA expression changes in lymphoblastoid cell lines in response to lithium treatment,” International Journal of Neuropsychopharmacology, vol. 12, no. 7, pp. 975–981, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. R. Zhou, P. Yuan, Y. Wang et al., “Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers,” Neuropsychopharmacology, vol. 34, no. 6, pp. 1395–1405, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. L. Bocchio-Chiavetto, E. Maffioletti, P. Bettinsoli et al., “Blood microRNA changes in depressed patients during antidepressant treatment,” European Neuropsychopharmacology, 2012. View at Publisher · View at Google Scholar
  39. K. Oved, A. Morag, M. Pasmanik-Chor et al., “Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers,” Pharmacogenomics, vol. 13, pp. 1129–1139, 2012. View at Publisher · View at Google Scholar
  40. A. Baudry, S. Mouillet-Richard, B. Schneider, J.-M. Launay, and O. Kellermann, “MiR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants,” Science, vol. 329, no. 5998, pp. 1537–1541, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. T. Matsubara, H. Funato, A. Kobayashi, M. Nobumoto, and Y. Watanabe, “Reduced glucocorticoid receptor α expression in mood disorder patients and first-degree relatives,” Biological Psychiatry, vol. 59, no. 8, pp. 689–695, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Fujimoto, S. Uchida, T. Watanuki et al., “Reduced expression of glyoxalase-1 mRNA in mood disorder patients,” Neuroscience Letters, vol. 438, no. 2, pp. 196–199, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. K. Otsuki, S. Uchida, T. Watanuki et al., “Altered expression of neurotrophic factors in patients with major depression,” Journal of Psychiatric Research, vol. 42, no. 14, pp. 1145–1153, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. J.-I. Iga, S.-I. Ueno, K. Yamauchi et al., “Gene expression and association analysis of LIM (PDLIM5) in major depression,” Neuroscience Letters, vol. 400, no. 3, pp. 203–207, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. J.-I. Iga, S.-I. Ueno, K. Yamauchi et al., “Altered HDAC5 and CREB mRNA expressions in the peripheral leukocytes of major depression,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 31, no. 3, pp. 628–632, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. J.-I. Iga, S.-I. Ueno, K. Yamauchi et al., “Serotonin transporter mRNA expression in peripheral leukocytes of patients with major depression before and after treatment with paroxetine,” Neuroscience Letters, vol. 389, no. 1, pp. 12–16, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. C.-W. Tsao, Y.-S. Lin, C.-C. Chen, C.-H. Bai, and S.-R. Wu, “Cytokines and serotonin transporter in patients with major depression,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 30, no. 5, pp. 899–905, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. L. Lima, S. Mata, and M. Urbina, “Allelic isoforms and decrease in serotonin transporter mRNA in lymphocytes of patients with major depression,” NeuroImmunoModulation, vol. 12, no. 5, pp. 299–306, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. R. H. Segman, T. Goltser-Dubner, I. Weiner et al., “Blood mononuclear cell gene expression signature of postpartum depression,” Molecular Psychiatry, vol. 15, no. 1, pp. 93–100, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. S. Spijker, J. S. van Zanten, S. de Jong et al., “Stimulated gene expression profiles as a blood marker of major depressive disorder,” Biological Psychiatry, vol. 68, no. 2, pp. 179–186, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Reichenberg, R. Yirmiya, A. Schuld et al., “Cytokine-associated emotional and cognitive disturbances in humans,” Archives of General Psychiatry, vol. 58, no. 5, pp. 445–452, 2001. View at Google Scholar · View at Scopus
  52. S. M. Kurian, H. Le-Niculescu, S. D. Patel et al., “Identification of blood biomarkers for psychosis using convergent functional genomics,” Molecular Psychiatry, vol. 16, no. 1, pp. 37–58, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Takahashi, H. Hayashi, Y. Watanabe et al., “Diagnostic classification of schizophrenia by neural network analysis of blood-based gene expression signatures,” Schizophrenia Research, vol. 119, no. 1–3, pp. 210–218, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. N. A. Bowden, J. Weidenhofer, R. J. Scott et al., “Preliminary investigation of gene expression profiles in peripheral blood lymphocytes in schizophrenia,” Schizophrenia Research, vol. 82, no. 2-3, pp. 175–183, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. M. R. Kuzman, V. Medved, J. Terzic, and D. Krainc, “Genome-wide expression analysis of peripheral blood identifies candidate biomarkers for schizophrenia,” Journal of Psychiatric Research, vol. 43, no. 13, pp. 1073–1077, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Maschietto, A. R. Silva, R. D. Puga et al., “Gene expression of peripheral blood lymphocytes may discriminate patients with schizophrenia from controls,” Psychiatry Research, vol. 200, pp. 1018–1021, 2012. View at Publisher · View at Google Scholar
  57. T. Hobara, S. Uchida, K. Otsuki et al., “Altered gene expression of histone deacetylases in mood disorder patients,” Journal of Psychiatric Research, vol. 44, no. 5, pp. 263–270, 2010. View at Publisher · View at Google Scholar
  58. M. Ventriglia, R. Zanardini, L. Pedrini et al., “VEGF serum levels in depressed patients during SSRI antidepressant treatment,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 33, no. 1, pp. 146–149, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. R. Belzeaux, C. Formisano-Tréziny, A. Loundou et al., “Clinical variations modulate patterns of gene expression and define blood biomarkers in major depression,” Journal of Psychiatric Research, vol. 44, no. 16, pp. 1205–1213, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. R. Belzeaux, A. Bergon, V. Jeanjean et al., “Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode,” Translational Psychiatry, vol. 2, p. e185, 2012. View at Google Scholar
  61. F. Mamdani, M. T. Berlim, M.-M. Beaulieu, A. Labbe, C. Merette, and G. Turecki, “Gene expression biomarkers of response to citalopram treatment in major depressive disorder,” Translational Psychiatry, vol. 1, article e13, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. A. O. Vik-Mo, A. B. Birkenaes, J. Fernø, H. Jonsdottir, O. A. Andreassen, and V. M. Steen, “Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients,” International Journal of Neuropsychopharmacology, vol. 11, no. 5, pp. 679–684, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. J. S. De, M. P. Boks, T. F. Fuller et al., “A gene co-expression network in whole blood of schizophrenia patients is independent of antipsychotic-use and enriched for brain-expressed genes,” PLoS One, vol. 7, Article ID e39498, 2012. View at Google Scholar
  64. P. Jia, L. Wang, A. H. Fanous, X. Chen, K. S. Kendler, and Z. Zhao, “A bias-reducing pathway enrichment analysis of genome-wide association data confirmed association of the MHC region with schizophrenia,” Journal of Medical Genetics, vol. 49, no. 2, pp. 96–103, 2012. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Debnath, D. M. Cannon, and G. Venkatasubramanian, “Variation in the major histocompatibility complex [MHC] gene family in schizophrenia: associations and functional implications,” Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 42, pp. 49–62, 2013. View at Google Scholar
  66. A. Gutiérrez-Fernández, A. González-Pinto, P. Vega, S. Barbeito, and C. Matute, “Expression of oligodendrocyte and myelin genes is not altered in peripheral blood cells of patients with first-episode schizophrenia and bipolar disorder,” Bipolar Disorders, vol. 12, no. 1, pp. 107–109, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. R. D. Beech, L. Lowthert, J. J. Leffert et al., “Increased peripheral blood expression of electron transport chain genes in bipolar depression,” Bipolar Disorders, vol. 12, no. 8, pp. 813–824, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. M. A. Zain, S. N. Jahan, G. P. Reynolds, N. Z. Zainal, S. Kanagasundram, and Z. Mohamed, “Peripheral PDLIM5 expression in bipolar disorder and the effect of olanzapine administration,” BMC Medical Genetics, vol. 13, p. 91, 2012. View at Google Scholar
  69. K. Kikuchi, J.-I. Iga, S. Tayoshi et al., “Lithium decreases VEGF mRNA expression in leukocytes of healthy subjects and patients with bipolar disorder,” Human Psychopharmacology, vol. 26, no. 4-5, pp. 358–363, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. H. Sugawara, K. Iwamoto, M. Bundo et al., “Effect of mood stabilizers on gene expression in lymphoblastoid cells,” Journal of Neural Transmission, vol. 117, no. 2, pp. 155–164, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. L. Lowthert, J. Leffert, A. Lin et al., “Increased ratio of anti-apoptotic to pro-apoptotic Bcl2 gene-family members in lithium-responders one month after treatment initiation,” Biology of Mood & Anxiety Disorders, vol. 2, p. 15, 2012. View at Google Scholar
  72. F. M. de la Vega, “Selecting single-nucleotide polymorphisms for association studies with SNPbrowserTM software,” Methods in Molecular Biology, vol. 376, pp. 177–193, 2007. View at Publisher · View at Google Scholar · View at Scopus
  73. P. DeRosse, T. Lencz, K. E. Burdick, S. G. Siris, J. M. Kane, and A. K. Malhotra, “The genetics of symptom-based phenotypes: toward a molecular classification of schizophrenia,” Schizophrenia Bulletin, vol. 34, no. 6, pp. 1047–1053, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. M. P. Vawter, F. Mamdani, and F. Macciardi, “An integrative functional genomics approach for discovering biomarkers in Schizophrenia,” Briefings in Functional Genomics, vol. 10, no. 6, pp. 387–399, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Michel, M. J. Schmidt, and K. Mirnics, “Immune system gene dysregulation in autism and schizophrenia,” Developmental Neurobiology, vol. 72, pp. 1277–1287, 2012. View at Google Scholar
  76. M.-L. Wong, C. Dong, J. Maestre-Mesa, and J. Licinio, “Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response,” Molecular Psychiatry, vol. 13, no. 8, pp. 800–812, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. J. Sainz, I. Mata, J. Barrera et al., “Inflammatory and immune response genes have significantly altered expression in schizophrenia,” Molecular Psychiatry, 2012. View at Publisher · View at Google Scholar
  78. A. Sequeira, M. V. Martin, B. Rollins et al., “Mitochondrial mutations and polymorphisms in psychiatric disorders,” Frontiers in Genetics, vol. 3, p. 103, 2012. View at Google Scholar
  79. E. S. Lander and N. J. Schork, “Genetic dissection of complex traits,” Science, vol. 265, no. 5181, pp. 2037–2048, 1994. View at Google Scholar · View at Scopus